

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-39 (cancelled).

40 (currently amended). A ~~disease associated, antigen activated~~ cytotoxic T-cell line, wherein the cells were activated by a disease associated antigen, and have exceeded a life-span of at least 40 PD.

41-59 (cancelled).

60 (previously presented). A T-cell line according to claim 40 wherein the functional profile of the T cell is not substantially altered during continuous growth.

61 (currently amended). A T-cell line according to claim 40 obtained by culturing a tissue sample from a human patient comprising ~~disease associated antigen activated~~ cytotoxic T-cells, said T cells having been activated by a disease associated antigen, in the presence of at least two factors which promote T-cell growth and one or more additional compounds promoting cytotoxic T cell selection and expansion exceeding 40 PD.

62 (previously presented). A T-cell line according to claim 61, wherein the factors which promote cytotoxic T-cell growth are selected from the group consisting of cytokines which promote cytotoxic T-cell growth.

63 (previously presented). A T-cell line according to claim 62, wherein the cytokines are selected from the group consisting of IL-2, IL-4, IL-7, IL-9, IL-10, IL-15, IL-16 and IL-12.

64 (previously presented). A T-cell line according to claim 63, wherein a combination of at least one of IL-2 or IL-15; and at least one of IL-4 or IL-7 or IL-9 is used.

65 (previously presented). A T-cell line according to claim 64, wherein a combination of IL-2 and IL-4 is used.

66 (previously presented). A T-cell line according to claim 62, wherein each of the cytokines is used in a concentration of at least 1 nM.

67 (previously presented). A T-cell line according to claim 66, wherein each of the cytokines is used in a concentration of at least 2.5 nM.

68 (previously presented). A T-cell line according to claim 61, wherein the tissue sample is selected from the group consisting of a biopsy, sputum, a swab, a gastric lavage, a bronchial lavage, an intestinal lavage, or another body fluid.

69 (previously presented). A T-cell line according to claim 68, wherein the tissue sample is selected from the group consisting of spinal, pleural, pericardial, synovial, blood and bone marrow body fluids.

70 (previously presented). A T-cell line according to claim 60, wherein the cytotoxic T-cells are cells having a CD8+ phenotype.

71 (previously presented). A T-cell line according to claim 60, wherein the cytotoxic T-cells are tumour infiltrating lymphocytes (TIL).

72 (previously presented). A cytotoxic T-cell line according to claim 61, wherein the one or more additional compounds are selected from the group consisting of GM-CSF, caspase inhibitors, Z-VAD, α -CD95, IL-10, IL-12, and IL-16.

73 (previously presented). A cytotoxic T-cell line according to claim 60, wherein the disease is of neoplastic origin.

74 (previously presented). A cytotoxic T-cell line according to claim 73, wherein the disease is selected from the group consisting of malignant melanoma, renal carcinoma, breast cancer, lung cancer, cancer of the uterus, prostatic cancer, hepatic carcinoma, and cutaneous lymphoma.

75 (previously presented). A pharmaceutical composition

comprising disease associated antigen activated cytotoxic T-cells according to claim 40 and one or more excipients selected from the group consisting of water, saline, dextrose, glycerol, and ethanol.

76 (previously presented). A pharmaceutical composition according to claim 75, wherein the T-cells are reactivated in the presence of one or more reactivating antigens.

77 (previously presented). A pharmaceutical composition according to claim 76, wherein each reactivating antigen or antigen is selected from the group consisting of disease associated antigens, alloantigens and super-antigens.

78 (previously presented). A pharmaceutical composition according to claim 77, wherein each reactivating antigen is a superantigen selected from the group consisting of SEA, SEB, SEC, SED, SEE, TSST, Streptococcus pyogenes enterotoxin A, B and C, and Mycoplasma arthritidis antigen.

79 (previously presented). A pharmaceutical composition according to claim 75, wherein the T-cells are incapable of further cell division.

80 (withdrawn - currently amended). A method of obtaining a cytotoxic T-cell line according to claim 40 comprising

- (a) obtaining a tissue sample comprising ~~disease associated, antigen activated~~ cytotoxic T cells, activated by a disease-associated antigen, from a human patient, and
- (b) culturing said tissue sample in the presence of at least two factors which promote T-cell growth and one or more additional compounds promoting cytotoxic T-cell selection and expansion exceeding 40 PD.

81 (withdrawn). A method according to claim 80 wherein the functional profile of the cytotoxic T-cells is not substantially altered during continuous culture.

82 (withdrawn). A method for treatment of neoplastic

diseases comprising administering a pharmaceutical composition comprising an immunologically effective amount of disease associated antigen activated cytotoxic T-cells isolated from the continuous T-cell line according to claim 40.

83 (withdrawn). A method according to claim 82 wherein the functional profile of the cytotoxic T-cells essentially corresponds to the initial functional profile of the cytotoxic T-cells of the tissues sample.

84 (cancelled).

85 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 60 PD.

86 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 100 PD.

87 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 150 PD.

88 (previously presented). A cell line according to claim 40 wherein the expected life-span is at least 200 PD.

89 (previously presented). A cell line according to claim 40 wherein the cells have exceeded a lifespan of 50 PD.

90 (previously presented). A cell line according to claim 40 wherein the cells have exceeded a lifespan of 60 PD.

91 (new). A cell line according to claim 61, which is obtained by culturing said cytotoxic T cells in the absence of peripheral blood mononuclear cell (PBMC) feeder cells.

92 (new). A cell line according to claim 40 wherein the cells are activated by a disease-specific antigen.

93 (new). A cytotoxic T-cell line, wherein the cells were activated by a disease associated antigen, and have an expected lifespan of at least 40 PD.

94 (new). A cell line according to claim 93, wherein the expected lifespan is at least 50 PD.